Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 27 of 27 results for abatacept

  1. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  2. Past appeals and decisions

    pegol, golimumab, abatacept and tocilizumab - review [ID537] 26 November 2015 TA141 Rheumatoid arthritis (refractory) -...

  3. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued

  4. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    In development [GID-TA10996] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with...

    Research recommendation
    Published
    15 March 2016

  6. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    23 April 2008

  7. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  8. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 April 2013

  9. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

    Highly specialised technologies guidance
    Published
    5 May 2022
    View recommendations

    Sections for HST20

  10. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Technology appraisal guidance
    Published
    24 August 2011

  11. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  12. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383